Heidelberg

DGAP-News: Heidelberg Pharma Announces Participation at Various Conferences

Retrieved on: 
Thursday, June 17, 2021
Baden, Ladenburg, Rhein-Neckar-Kreis, Geography of Germany, Heidelberg, Subdivisions of Germany, Heidelberg Pharma's proprietary ATAC technology, Heidelberg Pharma, HEIDELBERG PHARMA'S PROPRIETARY ATAC TECHNOLOGY, HEIDELBERG PHARMA

Ladenburg, Germany, 17 June 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present its proprietary ATAC technology at two upcoming scientific events.

Key Points: 
  • Ladenburg, Germany, 17 June 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced that they will present its proprietary ATAC technology at two upcoming scientific events.
  • Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany.
  • Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies.
  • Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA.

Affimed Announces Appointment of Uta Kemmerich-Keil to its Supervisory Board

Retrieved on: 
Wednesday, June 16, 2021

HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately.

Key Points: 
  • HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately.
  • We are pleased to welcome Uta to Affimeds Supervisory Board, said Dr. Thomas Hecht, Chairman of the Supervisory Board.
  • Uta brings unique and very deep and extensive executive experience in the life sciences industry.
  • Ms. Kemmerich-Keil brings senior executive, finance and M&A expertise to Affimed and over 20 years of executive experience in the pharmaceutical and chemical industry.

Heidelberg expecting profitable growth in FY 2021/2022 and subsequent years

Retrieved on: 
Wednesday, June 9, 2021
Baden, Heidelberg, Karlsruhe, Odenwald, Geography of Germany

"The comprehensive transformation Heidelberg initiated before the coronavirus pandemic hit has made the company leaner and more efficient.

Key Points: 
  • "The comprehensive transformation Heidelberg initiated before the coronavirus pandemic hit has made the company leaner and more efficient.
  • With solid economic development, this profitable upward trend looks set to continue in subsequent years, too.
  • This is down to the company's successful implementation of realignment measures, the focus on its profitable core business, and the expansion of growth areas.
  • Heidelberg sees considerable potential for sustained growth and increases in value in the futureabove all for packaging printing, digital business models, business in China, and new technology applications.

Heidelberg expecting profitable growth in FY 2021/2022 and subsequent years

Retrieved on: 
Wednesday, June 9, 2021
Baden, Heidelberg, Karlsruhe, Odenwald, Geography of Germany

"The comprehensive transformation Heidelberg initiated before the coronavirus pandemic hit has made the company leaner and more efficient.

Key Points: 
  • "The comprehensive transformation Heidelberg initiated before the coronavirus pandemic hit has made the company leaner and more efficient.
  • With solid economic development, this profitable upward trend looks set to continue in subsequent years, too.
  • This is down to the company's successful implementation of realignment measures, the focus on its profitable core business, and the expansion of growth areas.
  • Heidelberg sees considerable potential for sustained growth and increases in value in the futureabove all for packaging printing, digital business models, business in China, and new technology applications.

Affimed to Present at the Jefferies Virtual Healthcare Conference 2021

Retrieved on: 
Wednesday, May 26, 2021
Economy of New York City, NASDAQ, Finance, Financial markets, Investment

Heidelberg, Germany, May 26, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:30 a.m. Eastern Time.

Key Points: 
  • Heidelberg, Germany, May 26, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:30 a.m. Eastern Time.
  • A replay of the call will be archived on Affimeds website for 30 days after the call.
  • For more information on the conferences or to schedule a one-on-one meeting with Affimed management, please contact your conference representative or Alex Fudukidis via email at [email protected] or phone at +1 (917) 436-8102.
  • This innovative approach enabled Affimed to become the first company with a clinical-stage ICE.

Affimed Announces Virtual Annual General Meeting of Shareholders

Retrieved on: 
Thursday, May 20, 2021
XC2, Cancer immunotherapy

b'Heidelberg, Germany, May 20, 2021 \xe2\x80\x93 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2021 Annual General Meeting of Shareholders (the \xe2\x80\x9cAnnual Meeting\xe2\x80\x9d) will be held on June 15, 2021 at 17:30 PM CET (11:30 AM EDT).

Key Points: 
  • b'Heidelberg, Germany, May 20, 2021 \xe2\x80\x93 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its 2021 Annual General Meeting of Shareholders (the \xe2\x80\x9cAnnual Meeting\xe2\x80\x9d) will be held on June 15, 2021 at 17:30 PM CET (11:30 AM EDT).
  • Due to the continuing COVID-19 pandemic and out of concern for the health and safety of shareholders and other attendees, the Annual Meeting will be held virtually and can be followed by visiting www.virtualshareholdermeeting.com/AFMD2021 , in accordance with the instructions provided in the notice of the meeting.
  • The ROCK platform predictably generates customized innate cell engager (ICE\xc2\xae) molecules, which use patients\xe2\x80\x99 immune cells to destroy tumor cells.
  • This innovative approach enabled Affimed to become the first company with a clinical-stage ICE\xc2\xae.

Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer Cells

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Immune system, Medical specialties, Immunology, Natural killer cell, Antibody-dependent cellular cytotoxicity, T cell, Innate immune system, Macrophage

The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK (cbNK) cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity (ADCC).

Key Points: 
  • The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK (cbNK) cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity (ADCC).
  • AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages.
  • The ROCK platform predictably generates customized innate cell engager (ICE\xc2\xae) molecules, which use patients\xe2\x80\x99 immune cells to destroy tumor cells.
  • For more about the company\xe2\x80\x99s people, pipeline and partners, please visit: www.affimed.com .\nThis press release contains forward-looking statements.

DGAP-News: Heidelberger Druckmaschinen AG: Heidelberg wallboxes far exceed sales expectations - e-mobility business already profitable

Retrieved on: 
Tuesday, May 11, 2021
Academic disciplines, Baden, Heidelberg, Karlsruhe, Odenwald, Electric vehicle, Reliability engineering, Robustness, Articles, Geography of Germany

Furthermore, despite increased growth investments, Heidelberg has already achieved a positive margin for its electric vehicle charging stations (wallboxes).

Key Points: 
  • Furthermore, despite increased growth investments, Heidelberg has already achieved a positive margin for its electric vehicle charging stations (wallboxes).
  • The company has sold some 45,000 wallboxes to end customers since 2018.\n"With its wallboxes, Heidelberg has taken up a leading position in a market that is enjoying rapid growth.
  • Demand for our products is booming, and we\'ve significantly exceeded our sales targets for financial year 2020/21.
  • Customers appreciate the high quality, reliability, and robustness of Heidelberg wallboxes, and also their simple and versatile operation.

Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting I

Retrieved on: 
Monday, April 12, 2021

\xe2\x80\x9cDemonstrating that AFM24, in combination with NK cells, shows tumor regression in vivo is an important pre-clinical proof of concept.

Key Points: 
  • \xe2\x80\x9cDemonstrating that AFM24, in combination with NK cells, shows tumor regression in vivo is an important pre-clinical proof of concept.
  • AFM24-101 is a first-in-human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation and expansion study.
  • The ROCK\xc2\xae platform predictably generates customized innate cell engager (ICE\xc2\xae) molecules, which use patients\xe2\x80\x99 immune cells to destroy tumor cells.
  • For more about the company\xe2\x80\x99s people, pipeline and partners, please visit: www.affimed.com .\nThis press release contains forward-looking statements.